

July 13, 2023

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

Sub: Reconciliation of Share Capital Audit Report for the Quarter ended June 30, 2023

Enclosed please find herewith the Reconciliation of Share Capital Audit Report issued by M/s. Savita Jyoti Associates, Company Secretaries for the Quarter ended June 30, 2023.

Please take the same on records.

Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary & Compliance Officer

Encl: as above

SAVITA JYOTI ASSOCIATES
COMPANY SECRETARIES

CS. SAVITA JYOTI, B.Com., F.C.S.

RECONCILIATION OF EQUITY SHARE CAPITAL AUDIT REPORT

1.	For Quarter Ended	30 th June, 2023					
2.	ISIN	INE03Q201024					
3.	Face Value	Rs.2/-					
4.	Name of the Company	Glenmark Life Sciences Limited					
5.	Registered Office Address	Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur, Maharashtra, 413213					
6.	Correspondence Address	4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri East Mumbai 400099					
7.	Telephone and Fax Numbers	Tel.: 91 22 68297979 Fax : NIL					
8.	Email Address	complianceofficer@glenmarklifesciences.com					
9.	Names of the Stock Exchanges where the Company's Securities are listed.	BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA LIMITED					
		NUMBER OF SHARES			% OF TOTAL ISSUED CAPITAL		
10.	Issued Capital	12,25,27,172			100%		
11.	Listed Capital	12,25,27,172			100%		
12.	Held in Dematerialised form in CDSL	89,27,422			7.29%		
13.	Held in Dematerialised form in NSDL	11,35,99,750			92.71%		
14.	Held in Physical Form	00			0.00		
15.	Total Number of Shares 12+13+14	12,25,27,172			100%		
16.	Reasons for difference if any, between (10&11), (11&15)	N.A.					
17.	Certifying the details of changes in share capital during the quarter under consideration as per Table below:						
	Particulars	No of shares	Applied/ not Applied for Listing	Listed on Stock Exchanges	Whether intimated to CDSL	Whether intimated to NSDL	In-Principle Approval Pending for SE
	NIL	NIL	NIL	NIL	NIL	NIL	NIL

SAVITA JYOTI ASSOCIATES
COMPANY SECRETARIES

CS. SAVITA JYOTI, B.Com., F.C.S.

:II:

18.	Register of Members is Updated: If not updated upto which date:	YES N.A.		
19.	Reference of previous quarter with regard to excess dematerialized shares, if any:	NIL		
20.	Has the Company resolved the matter mentioned in point no.19 above, in the quarter? If not, the reason why?	N.A.		
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:			
Total No. of Demat Requests		No. of Requests	No. of Shares	Reasons for delay
Confirmed after 21 days		NIL	NIL	NIL
Pending for more than 21 days		NIL	NIL	NIL
22.	Name, Telephone & Fax No. of the Compliance Officer of the Company:	Mr. Rudolf Corriea Company Secretary & Compliance Officer Membership No. ACS 27911 Tel: 91 22 68297979; Fax No: NIL		
23.	Name, Address, Telephone & Fax No., Regn. No. of the Practicing Company Secretary:	Mrs. Savita Jyoti Savita Jyoti Associates E-86, Sainikpuri, Secunderabad – 500 094. Telephone No. 040-27110559 Registration No. FCS 3738; CP No: 1796		
24.	Appointment of Common Agency for Share Registry Work:	Yes KFin Technologies Limited Tower – B, Plot No 31 & 32, Selenium Building, Financial District, Nanakramguda, Gachibowli, Hyderabad – 500 032, Telangana, India, SEBI registration No: INR000000221 Tel: 040 – 67162222; Fax: 040- 23001153; Email: glenmark.ipo@kfintech.com ; einward.ris@kfintech.com website: www.kfintech.com		
25.	Any other details that the auditor may like to provide. (e.g. BIFR Company, Delisting from Stock Exchanges,	NIL		

FOR SAVITA JYOTI ASSOCIATES

Savita Jyoti

SAVITA JYOTI

Place: Hyderabad

Date: 12/07/2023

UDIN: F003738E000590753

SAVITA JYOTI, FCS 3738
Practicing Company Secretary
Certificate of Practice No. 1796